Xilio Therapeutics (fka Akrevia Therapeutics), a Waltham, MA-based company developing potent, tumor-selective immuno-oncology (IO) therapies for patients with cancer, closed a $100.5m Series B financing.
The round was led by Takeda Ventures, with participation from new investors SV Health Investors, MRL Ventures Fund, RiverVest Venture Partners, Bay City Capital, Solasta Ventures, M Ventures, and Ipsen Ventures, which joined existing investors F-Prime Capital and Atlas Venture in the syndicate.
Founded in 2016 and led by Rene Russo, Chief Executive Officer, Xilio Therapeutics is is a biotechnology company developing its proprietary technology to create a new class of ultra-potent IO therapies that are activated selectively within the tumor.
These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment.
XTX201 (IL-2) and XTX101 (aCTLA4 mAb) have demonstrated tumor-selective activity in preclinical models, significantly widening the potential therapeutic index for these therapies. | To read full story, visit https://startuparound.com/read/1583242210.7390628/Xilio-Therapeutics-Raises-$100.5M-in-Series-B-Financing?ref=audio_experience